Maria Trent1, Carol Thompson2, Kathy Tomaszewski3. 1. Section on Adolescent Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Population, Family, and Reproductive Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Electronic address: mtrent2@jhmi.edu. 2. Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Section on Adolescent Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
PURPOSE: To evaluate the feasibility, acceptability, and preliminary effectiveness of DepoText, a text messaging reminder system designed to improve moderately long-acting reversible contraception appointment attendance among young urban adolescent girls and young adult women using Depo-Provera. METHODS:Female patients aged 13-21 years willing to be randomized, using Depo-Provera, and owning a cell phone with text messaging were recruited from an urban academic practice in a community with high rates of unplanned pregnancy for this institutional review board-approved randomized controlled pilot trial. Participants completed a baseline Web-based survey and were followed for three injection cycles. Intervention participants received welcome, appointment, and healthy self-management messages using the Compliance for Life short messaging system platform over each injection cycle. Compliance for Life recorded outgoing and incoming communications, and patients were tracked for clinical behaviors. The log-transformed number of days between scheduled appointment and injection was analyzed using linear regression. RESULTS: Recruitment data show 95% eligibility and 91% enrollment rates with maximum enrollment completion in 3 months. Most were African-American and resided in low-income, single-parent, and mother-headed households. Most participants had cell phone plans that included unlimited text messaging and Internet access and completed all three Depo-Provera cycles. Intervention participants returned closer to their scheduled appointments than their control peers for the first visit (Β = -.75; 95% confidence interval, -1.4 to .06; p = .03) but not for the second and third visits. CONCLUSIONS: The DepoText intervention is acceptable, feasible, and shows short-term preliminary efficacy for improving clinic attendance for moderately long-acting reversible contraception appointments. Additional research exploring the cost and longitudinal prevention effectiveness is warranted.
RCT Entities:
PURPOSE: To evaluate the feasibility, acceptability, and preliminary effectiveness of DepoText, a text messaging reminder system designed to improve moderately long-acting reversible contraception appointment attendance among young urban adolescent girls and young adult women using Depo-Provera. METHODS: Female patients aged 13-21 years willing to be randomized, using Depo-Provera, and owning a cell phone with text messaging were recruited from an urban academic practice in a community with high rates of unplanned pregnancy for this institutional review board-approved randomized controlled pilot trial. Participants completed a baseline Web-based survey and were followed for three injection cycles. Intervention participants received welcome, appointment, and healthy self-management messages using the Compliance for Life short messaging system platform over each injection cycle. Compliance for Life recorded outgoing and incoming communications, and patients were tracked for clinical behaviors. The log-transformed number of days between scheduled appointment and injection was analyzed using linear regression. RESULTS: Recruitment data show 95% eligibility and 91% enrollment rates with maximum enrollment completion in 3 months. Most were African-American and resided in low-income, single-parent, and mother-headed households. Most participants had cell phone plans that included unlimited text messaging and Internet access and completed all three Depo-Provera cycles. Intervention participants returned closer to their scheduled appointments than their control peers for the first visit (Β = -.75; 95% confidence interval, -1.4 to .06; p = .03) but not for the second and third visits. CONCLUSIONS: The DepoText intervention is acceptable, feasible, and shows short-term preliminary efficacy for improving clinic attendance for moderately long-acting reversible contraception appointments. Additional research exploring the cost and longitudinal prevention effectiveness is warranted.
Authors: Gareth V Furber; Ann E Crago; Kevin Meehan; Tom D Sheppard; Ken Hooper; Dorothy T Abbot; Stephen Allison; Clive Skene Journal: J Adolesc Health Date: 2011-01 Impact factor: 5.012
Authors: John S Santelli; Laura Duberstein Lindberg; Lawrence B Finer; Susheela Singh Journal: Am J Public Health Date: 2006-11-30 Impact factor: 9.308
Authors: Deborah Levine; Jacqueline McCright; Loren Dobkin; Andrew J Woodruff; Jeffrey D Klausner Journal: Am J Public Health Date: 2008-01-30 Impact factor: 9.308
Authors: Gina M Secura; Jenifer E Allsworth; Tessa Madden; Jennifer L Mullersman; Jeffrey F Peipert Journal: Am J Obstet Gynecol Date: 2010-06-11 Impact factor: 8.661
Authors: Maria Trent; Shang-en Chung; Michael Burke; Allen Walker; Jonathan M Ellen Journal: J Pediatr Adolesc Gynecol Date: 2009-09-03 Impact factor: 1.814
Authors: Cara R Muñoz Buchanan; Kathy Tomaszewski; Shang-En Chung; Krishna K Upadhya; Alexandra Ramsey; Maria E Trent Journal: Clin Pediatr (Phila) Date: 2017-02-13 Impact factor: 1.168
Authors: Maria Trent; Shang-En Chung; Charlotte Gaydos; Kevin D Frick; Jennifer Anders; Steven Huettner; Richard Rothman; Arlene Butz Journal: Eur Med J Reprod Health Date: 2016-08
Authors: Lauren S Chernick; Melissa S Stockwell; Ariana Gonzalez; Jameson Mitchell; Anke Ehrhardt; Susanne Bakken; Carolyn L Westhoff; John Santelli; Peter S Dayan Journal: J Adolesc Health Date: 2020-09-15 Impact factor: 5.012
Authors: Natasha Mack; Tineke J Crawford; Jeanne-Marie Guise; Mario Chen; Thomas W Grey; Paul J Feldblum; Laurie L Stockton; Maria F Gallo Journal: Cochrane Database Syst Rev Date: 2019-04-23